UNSPSC 51371803: Meperidine or pethidine

This classification denotes an opioid receptor agonist with the molecular formula C15H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E338QE28F, chemically known as 4-piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester, hydrochloride but generally known as meperidine, which bears US NIH Compound Identifier 4058. European Medicines Agency schedules Pethidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09738MIG. The term MEPERIDINE is an International Non-Proprietary Name.

World Health Organization schedules meperidine in its Anatomical Therapeutic Chemical (ATC) Classification. Meperidine or pethidine bears US NLM identifiers UMLS ID C0025376 and NCI Concept Code C71632. SMILES: CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.

UNSPSC 51371803 Meperidine or pethidine is a Commodity code that captures state and local government procurement of controlled pharmaceutical substances and related products, though recent opportunities show substantial mismatch between the code's nominal scope and actual buying activity. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems (a life-safety pharmaceutical), generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and a direct-to-manufacturer prescription program—none of which are meperidine specifically. State and local issuing bodies soliciting pharmaceutical products include county health departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple jurisdictions. The buying pattern reflects healthcare support and community health initiatives rather than the opioid-class controlled substance the code nominally identifies.

Solicitations are concentrated in Florida and Minnesota, with Texas involvement at the state-agency level. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023). The Minnesota Department of Administration, through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program. The code shows measurable recent activity, but procurement professionals should verify that opportunities tagged 51371803 align with their firm's actual product or service capability, as the nominal meperidine scope does not track current state and local buying patterns in these three recent cases.